Author Affiliation: Interventional Cardiology Division, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada (Qh.firstname.lastname@example.org).
To the Editor: The LateTIME trial findings1 suggest a lack of benefit from intracoronary delivery of bone marrow mononuclear cells (BMCs) 2 to 3 weeks after primary percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI) and depressed left ventricular (LV) function. However, further clarification is needed to better appreciate the study conclusions.
Ly HQ. Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction. JAMA. 2012;307(10):1022-1024. doi:10.1001/jama.2012.278